RecruitingNot ApplicableNCT04297085

Prospective Cohort Study on the Determinants of Venous THromboembolic Recurrence

Prospective Cohort Study on the Determinants of Venous THromboembolic Recurrence. BREIZH-Cohorte


Sponsor

University Hospital, Brest

Enrollment

3,400 participants

Start Date

May 28, 2020

Study Type

INTERVENTIONAL

Conditions

Summary

The main objective of the BREIZH-Cohorte study is to determine the incidence of recurrent short, medium and long-term thromboembolic venous disease as well as risk factors for recurrence in two specific populations: patients under 50 years of age, men and women (5 year recurrence), as well as cancer patients (all ages) (1 year recurrence).


Eligibility

Inclusion Criteria4

  • Subject aged 18 or over, or a minor with the consent of the parents and the minor, presenting with a thromboembolic venous disease
  • and under or any age if active cancer
  • Affiliated to social security
  • Accepting to participate in the study.

Exclusion Criteria2

  • Inability to communicate (comprehension disorder).
  • Refusal to participate.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALBiologic sample

Biological samples will be taken from the subjects included


Locations(4)

CHRU Brest

Brest, France

HIA Clermont Tonnerre Brest

Brest, France

CH Morlaix

Morlaix, France

CH de Cornouaille

Quimper, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04297085